Breaking Finance News

Entellus Medical Inc (NASDAQ:ENTL) has been downgraded to Buy in a statement by BidaskClub earlier today.

Having a price of $15.89, Entellus Medical Inc (NASDAQ:ENTL) traded -1.40% lower on the day. With the last stock price up 12.57% from the two hundred day average, compared with the Standard & Poor's 500 Index which has increased 0.05% over the same period. ENTL has recorded a 50-day average of $16.93 and a two hundred day average of $14.98. Trade Volume was up over the average, with 233,111 shares of ENTL changing hands over the typical 177,650

BidaskClub has downgraded Entellus Medical Inc (NASDAQ:ENTL) to Buy in a statement released on Saturday July 08, 2017.

Recent Performance Chart

Entellus Medical Inc (NASDAQ:ENTL)

Entellus Medical Inc has with a one year low of $11.47 and a one year high of $22.63 and has a market capitalization of $0.

General Company Details For Entellus Medical Inc (NASDAQ:ENTL)

Entellus Medical, Inc. is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment. The Company's XprESS Multi-Sinus Dilation family of products consists of its XprESS Pro device, its XprESS LoProfile device and its XprESS Ultra device. The MiniFESS family of surgical instruments includes eight devices designed to enable physicians to perform various surgical procedures. The Fiagon Image Guidance System (IGS) consists of a navigation unit, navigation sensor, software instruments and a patient localizer.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.